Fig. 1
From: Vaccination with inhibin-α provides effective immunotherapy against testicular stromal cell tumors
Immunogenicity of recombinant mouse inhibin-α (rmInα). a Coomassie blue staining (left panel) showed migration of affinity purified and HPLC purified rmInα on an SDS-PAGE gel at the anticipated molecular mass of 39.56 kDa. This correct molecular mass migration was confirmed by Western blot analysis of the HPLC purified protein using an antibody specific for mouse inhibin-α (right panel). b 8-10 week old male BALB/c mice were immunized with rmInα, and ten days later, LNC were tested for recall proliferative responsiveness. c Immunogenicity was confirmed by ELISPOT analysis of type-1, type-2, and type-17 T cells expressing IFNγ, IL-5, and IL-17, respectively. d Immunogenicity was also confirmed by ELISA measurement IFNγ, IL-5, and IL-17 concentrations in supernatants of rmInα primed LNC reactivated with antigen. e ELISPOT analysis of responses from purified T cell subpopulations showed that the response to rmInα was elicited predominantly from CD4+ T cells. f Serum antibody titers from BALB/c male mice 3 weeks after immunization with rmInα showed differential production of IgG isotypes. Error bars indicate ± SE